Diagnostic methodology for the biochemical recurrence of prostate cancer after radiotherapy;Metodología diagnóstica ante la recidiva bioquímica después de la radioterapia

Archivos Espanoles de Urologia

Volumn 59, Issue 10, 2006, Pages 1053-1062

  Pijoan, Javier Maldonado ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Biochemical recurrence; Definitions; Radical radiotherapy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BLOOD; HUMAN; MALE; PROSTATE TUMOR; SECOND CANCER; TUMOR RECURRENCE;

HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 33846524798     PISSN: 00040614     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. HODGSON, D.; CATION, C.; WARDE, P. y cols.: "The impact of irregularly rising prostate specific antigen and "impending failure" on the apparent outcome of localized prostate cancer following radiotherapy". Int. J. Radiat Oncol. Biol. Phys., 49: 957, 2001.
2. PICKLES, T.; DUNCAN, G.; KIM SING, C. y cols.: "PSA relapse definitions the Vancouver rules show superior predictive power". Int. J. Radiat. Oncol. Biol. Phys., 43: 699, 1999.
3. JOHNSTONE, P.; McFARIAND, J.; RIFFENBURGH, R. y cols.: "Efficacy of digital rectal examination after radiotherapy for prostate cancer". J. Urol., 166: 1684, 2001.
4. CRITZ, F.; WILLIAMS, W.; HOLLADAY, C. y cols.: "Post treatment PSA < or + 0.2 ngImI defines disease freedom after radiotherapy for prostate cancer using modern techniques". Urology, 54: 968, 1999.
5. CROOK, J.; CHOAN, E.; PERRY, G. y cols.: "Serum prostate specific antigen profile following radiotherapy for prostate cancer: implications for patterns of failure and definition of cure". Urology, 51: 566, 1998.
6. HANLON, A.; DIRATZOUIAN, H.; HANKS, G.: "Posttreatment prostate specific antigen nadir highly predictive of distant failure and death from prostate cancer". Int. J. Radiat. Oncol. Biol. Phys., 53: 297, 2002.
7. HANLON, A.; HANKS, G.: "Scrutiny of the ASTRO consensus definition of biochemical failure in irradiated prostate cancer patients demonstrates its usefulness and robustness. American Society for Therapeutic Radiology and Oncology". Int. J. Radiat. Oncol. Biol. Phys., 46: 559, 2000.
8. POLLACK, A.; ZAGARS, G.; ANTOLAK, J. y cols.: "Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial". Int. J. Radiat. Oncol. Biol. Phys., 54: 677, 2002.
9. ROACH, M.: "The role of PSA in the radiotherapy of prostate cancer". Oncology, 10: 1143, 1996.
10. HORWITZ, E.; VICINI, F.; ZIAJA, E. y cols.: "The correlation between the ASTRO consensus panel definition of biochemical failure and clinical outcome for patients with prostate cancer treated with external beam irradiation". American Society of Therapeutic Radiology and Oncology. Int. J. Radiat. Oncol. Biol. Phys., 41: 267, 1998.
11. TAYLOR, J.; GRIFFITH, K.; SANDLER, H.: "Definitions of biochemical failure in prostate cancer following radiation therapy". Int. J. Radiat. Oncol. Biol. Phys., 50: 1212, 2001.
12. ASTRO consensus statement: Guidelines for PSA following Radiation Therapy. Int. J. Radiat. Oncol. Biol. Phys., 37: 1035, 1997.
13. VICINI, F.A.; KESTIN, L.L.; MARTINEZ, A.A.: "The importance of adequate follow-up in defining treatment success after external beam irradiation for prostate cancer". Int. J. Radiat. Oncol. Biol. Phys., 45: 553, 1999.
14. THAMES, H.; KUBAN, D.; LEVY, L. y cols.: "Comparison of alternative biochemical failure definitions based on clinical outcomes in 4389 prostate cancer patients treated by external beam radiotherapy between 1986-1995". Int. J. Radiat. Oncol. Biol. Phys., 57: 929, 2003.
15. MERRICK, G.S.; BUTTLER, W.M.; GALBREATH, R.W. y cols.: "Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer". Int. J. Radiat. Oncol. Biol. Phys., 51: 41, 2001.
16. SYLVESTER, J.E.; BLASKO, J.C.; GRIMM, P.D. y cols.: "Ten-year bio-chemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: The Seattle experience". Int. J. Radiat. Oncol. Biol. Phys., 57: 944, 2003.
17. HANKS, G.E.; PAJAK, T.F.; PORTER, A. y cols.: "Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02". J. Clin. Oncol., 21: 3972, 2003.
18. TAYLOR, J.M.; YTT, M.; SANDLER, H.M.: "Individualized predictions of disease progression following radiation therapy for prostate cancer". J. Clin. Oncol., 23: 816, 2005.
19. SUBAN, D.A.; THAMES, H.D.; LEVY, L.B. y cols.: "Long-term multiinstitutional analysis of stage TI-T2 prostate cancer treated with radiotherapy in the PSA era". Int. J. Radial. Oncol. Biol. Phys., 57: 915, 2003.
20. ROACH, M.; HANKS, G.; THAMES, H. y cols.: "Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference". Int. J. Radial. Oncol. Biol. Phys., 65: 965, 2006.
21. PICKLES, T.; AGRANOVICH, A.; BERTHELET, E. y cols.: "Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma". Cancer, 94: 362, 2002.
22. BUYYOUNOSKI, M.; HANLON, A.; EISENBERG, D. y cols.: "Defining Biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer". Int. J. Radial. Oncol. Biol. Phys., 63: 1455, 2005.
23. PICKETT, B.; TEN HAKEN, R.K.; KURHANEWIEZ, J. y cols.: "Time to metabolic atrophy after permanent prostate seed implantation based on magnetic resonance spectroscopic imaging". Int. J. Radiat. Oncol. Biol. Phys., 59: 665, 2004.
24. DAS, P.; CHEN, M.; VALENTINE, K. y cols.: "Using the magnitude of PSA bounce after MRI-guided prostate brachytherapy to distinguish recurrence, benign precipitating factors, and idiopathic bounce". Int. J. Radiat. Oncol. Biol. Phys., 54: 698, 2002.
25. HANLON, A.; PINOVER, W.; HORWITZ, E. y cols.: "Patterns and fate of PSA bouncing following 3DCRT". Int. J. Radiat. Oncol. Biol. Phys., 55: 845, 2001.
26. ROSSER, C.; KUBAN, D.; LEVY, L. y cols.: "Prostate specific antigen bounce phenomenon after external beam radiation for clinically localized prostate cancer". J. Urol., 168: 2001, 2002.
27. CROOK, J.; ROBERTSON, S.; COLLIN, G. y cols.: "Clinical relevance of trans-rectal ultrasound, biopsy, and serum prostate-specific antigen following external beam radiotherapy for carcinoma of the prostate". Int. J. Radiat. Oncol. Biol. Phys., 27: 31, 1993.
28. CROOK, J.: PERRY, G.; ROBERTSON, S. y cols.: "Routine prostate biopsies following radiotherapy for prostate cancer: results for 226 patients". Urology, 45: 624, 1995.
29. CROOK, J.; BAHADUR, Y.; BOCICK, R. y cols.: "Radiotherapy for localized prostate carcinoma. The correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcome as assessed by systematic biopsy and serum prostate specific antigen". Cancer, 79: 328, 1997.
30. LUKKA, H.; HAYTER, C.; JONES, E. y cols.: "Assessment of post-radiation prostatic needle biopsies for residual adenocarcinoma: a study of interobserver agreement (abstract)". Radiother Oncol. 65: 13, 2002.
31. COX, J.; GALLAGHER, M.; HAMMOND, E. y cols.: "Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy". American Society for Therapeutic Radiology and Oncology consensus panel. J. Clin. Ocol., 17: 1155, 1999.
32. ZELEFSKY, M.J.; CHAN, H.M.; FUKS, Z. y cols.: "Correlation of long term bioquemical outcome with post treatment biopsy results for patients treated with 3-D dimensional conformal radiotherapy for prostate cancer". Int. J. Radiat. Oncol. Biol. Phys, 60: 170, 2004.
33. ALBERTSEN, P.; HANLEY, J.; HARLAN, L. y cols.: "The positive yield of imaging studies in the evaluation of men with newly diagnosed prostate cancer: a population based analysis". J. Urol., 163: 1138, 2000.
34. O'SULLIVAN, J.; COOK, G.: "A review of the efficacy of bone scanning in prostate and breast cancer". Q. J. Nucl. Med., 46: 152, 2002.
35. MILLER, P.; EARDLEY, L.; KIRBY, R.: "Prostate specific antigen and bone scan correlation in the staging and monitoring of patients with prostatic cancer". Br. J. Urol., 70: 295, 1992.
36. TERRIS, M.; KLONECKE, A.; McDOUGALL, L. y cols.: "Utilization of bone scans in conjunction with prostate-specific antigen levels in the surveillance for recurrence of adenocarcinoma after radical prostatectomy". J. Nucl. Med., 32: 1713, 1991.
37. HINKLE, G.; BURGERS, J.; NEAL, C. y cols.: "Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using Indium-111 capromab pendetide". Cancer, 83: 739, 1998.
38. PRICE, D.T.; COLEMAN, R.E.; LIAO, R.P. y cols.: "Comparison of (18 F) fluorocholina and (18F) fluorodesoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer". J. Urol., 168: 273, 2002.
39. SALMINEN, E.; HOGG, E.; BINNS, D. y cols.: "Investigations with FDG-PET scanning in prostate cancer show limited value for clinical practice". Acta oncol., 41: 425, 2002.
40. TOMBAL, B.: "Alternatives to imaging". Prostate Cancer Symposium, San Francisco. p-85, ASCO 2006.